Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.89)
# 1,707
Out of 4,711 analysts
79
Total ratings
47.46%
Success rate
7.93%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $11.57 | +29.65% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $4.05 | +97.53% | 7 | Mar 11, 2024 | |
| ACAD ACADIA Pharmaceuticals | Downgrades: Hold | $25 | $16.87 | +48.19% | 15 | Dec 14, 2023 | |
| IMVT Immunovant | Initiates: Buy | $50 | $25.86 | +93.35% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $135.42 | +0.43% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $3.97 | +303.02% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $15.22 | +307.36% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.86 | +545.16% | 6 | Dec 12, 2023 | |
| SAGE Sage Therapeutics | Initiates: Hold | $21 | $5.61 | +274.33% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $118.97 | -8.38% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.85 | +332.43% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.19 | +740.34% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $5 | $0.66 | +657.58% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $8.65 | -30.64% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $3.10 | +577.42% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $70.44 | -67.35% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $14.55 | +147.42% | 2 | Jul 11, 2017 |
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $11.57
Upside: +29.65%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $4.05
Upside: +97.53%
ACADIA Pharmaceuticals
Dec 14, 2023
Downgrades: Hold
Price Target: $25
Current: $16.87
Upside: +48.19%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $25.86
Upside: +93.35%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $135.42
Upside: +0.43%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $3.97
Upside: +303.02%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $15.22
Upside: +307.36%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.86
Upside: +545.16%
Sage Therapeutics
Dec 12, 2023
Initiates: Hold
Price Target: $21
Current: $5.61
Upside: +274.33%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $118.97
Upside: -8.38%
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $1.85
Upside: +332.43%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $1.19
Upside: +740.34%
Nov 11, 2022
Maintains: Buy
Price Target: $7 → $5
Current: $0.66
Upside: +657.58%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $8.65
Upside: -30.64%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $3.10
Upside: +577.42%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $70.44
Upside: -67.35%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $14.55
Upside: +147.42%